- The Food and Drug Administration on Friday approved the first version of over-the-counter (OTC) naloxone from a nonprofit company, a move that could bring cheap and even free doses of the opioid overdose drug to Americans who need it most. RiVive, made by Harm Reduction Therapeutics, is the second over-the-counter naloxone product approved by FDA this year. Each RiVive device contains one dose of naloxone. It will be exclusively available in twin packs containing two single-dose devices of 3 milligrams each. The company said it anticipates RiVive will be available in early 2024, primarily to harm-reduction organizations and state governments for costs lower than other opioid antagonist nasal sprays. (Articles here and here)
July 31, 2023
Opioid/Substance Use Disorders | Tea Leaves